Revvity (NYSE:RVTY) Stock Price Target Raised at Barclays

Revvity (NYSE:RVTY) had its price objective increased by Barclays from $160.00 to $175.00 in a research note released on Wednesday,Benzinga reports. They currently have an equal weight rating on the stock.

Several other equities analysts have also recently weighed in on the stock. Zacks Research raised shares of Revvity from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. TD Cowen boosted their price objective on Revvity from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Evercore restated an “outperform” rating on shares of Revvity in a report on Wednesday, August 5th. UBS Group began coverage on Revvity in a research report on Wednesday, September 9th. They set a “neutral” rating and a $140.00 target price on the stock. Finally, KeyCorp upped their price target on Revvity from $125.00 to $165.00 and gave the stock an “overweight” rating in a report on Friday, September 4th. Six investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $133.86.

Revvity Stock Performance

RVTY opened at $159.68 on Wednesday. Revvity has a 1-year low of $81.22 and a 1-year high of $171.74. The company has a market cap of $17.82 billion, a price-to-earnings ratio of 29.46, a PEG ratio of 2.95 and a beta of 1.08. The company’s fifty day moving average price is $146.58 and its two-hundred day moving average price is $112.84. The company has a current ratio of 2.65, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.30 by $0.08. The firm had revenue of $728.90 million during the quarter, compared to analysts’ expectations of $694.73 million. Revvity had a net margin of 8.61% and a return on equity of 8.64%. The business’s revenue was up 4.3% on a year-over-year basis. During the same period last year, the company earned $1.18 earnings per share. On average, analysts expect that Revvity will post 5.41 EPS for the current fiscal year.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 12th. Shareholders of record on Friday, January 22nd will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date of this dividend is Friday, January 22nd. Revvity’s dividend payout ratio is presently 13.33%.

Insider Activity

In other news, insider Maxwell Krakowiak sold 1,631 shares of the company’s stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $144.53, for a total value of $235,728.43. Following the completion of the transaction, the insider directly owned 14,781 shares of the company’s stock, valued at $2,136,297.93. This represents a 9.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Tajinder S. Vohra sold 7,330 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total value of $1,032,650.40. Following the completion of the transaction, the insider directly owned 6,635 shares of the company’s stock, valued at approximately $934,738.80. This represents a 52.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 9,045 shares of company stock valued at $1,281,439. Company insiders own 0.85% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Lido Advisors LLC grew its stake in Revvity by 27.3% in the 3rd quarter. Lido Advisors LLC now owns 4,510 shares of the company’s stock valued at $690,000 after purchasing an additional 968 shares during the period. New York Life Investment Management LLC raised its stake in shares of Revvity by 4.6% during the 3rd quarter. New York Life Investment Management LLC now owns 31,457 shares of the company’s stock worth $4,809,000 after purchasing an additional 1,392 shares during the period. AlphaCore Capital LLC raised its stake in shares of Revvity by 135.9% during the 3rd quarter. AlphaCore Capital LLC now owns 5,015 shares of the company’s stock worth $767,000 after purchasing an additional 2,889 shares during the period. Fulcrum Asset Management LLP bought a new stake in shares of Revvity during the 3rd quarter worth $514,000. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Revvity by 0.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,248,998 shares of the company’s stock worth $335,236,000 after buying an additional 21,124 shares during the last quarter. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Key Stories Impacting Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity beat third-quarter estimates, reporting adjusted EPS of $1.38 versus a $1.30 consensus and revenue of $728.9 million versus $694.7 million. Revenue increased 4.3% year over year, with Life Sciences strength and margin expansion cited, and the company raised its 2026 outlook. Q3 earnings and outlook
• Positive Sentiment: CFRA upgraded the stock from Hold to Buy. TD Cowen also raised its price target to $185 and maintained a Buy rating, signaling further potential upside. TD Cowen price-target change
• Neutral Sentiment: Other analysts raised targets but kept more cautious ratings: Barclays set $175 with Equal Weight, RBC set $172 with Sector Perform, and JPMorgan set $160 with Neutral. The range of views suggests analysts see improvement, but not uniform conviction. JPMorgan price-target change
• Negative Sentiment: Valuation may temper enthusiasm: coverage questioned whether the stock is now too expensive, while JPMorgan’s new target is close to the referenced share price. This could contribute to a pullback even after the earnings beat. Valuation and dividend coverage

About Revvity

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.